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Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined
immunodeficiency and a high predisposition to lymphoid malignancies. The majority of
NBS patients are identified with a homozygous five base pair deletion in the Nibrin (NBN)
gene (c.657_661del5, p.K219fsX19) with a founder effect observed in Caucasian
European populations, especially of Slavic origin. We present here an analysis of a
cohort of 136 NBS patients of Eastern Slav origin across Belarus, Ukraine, Russia, and
Latvia with a focus on understanding the geographic distribution, incidence of malignancy,
and treatment outcomes of this cohort. Our analysis shows that Belarus had the highestorg January 2021 | Volume 11 | Article 6024821
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Frontiers in Immunology | www.frontprevalence of NBS (2.3 per 1,000,000), followed by Ukraine (1.3 per 1,000,000), and Russia
(0.7 per 1,000,000). Of note, the highest concentration of NBS cases was observed in the
western regions of Belarus and Ukraine, where NBS prevalence exceeds 20 cases per
1,000,000 people, suggesting the presence of an “Eastern Slavic NBS hot spot.” The median
age at diagnosis of this cohort ranged from 4 to 5 years, and delay in diagnosis was more
pervasive in smaller cities and rural regions. A total of 62 (45%) patients developed
malignancies, more commonly in males than females (55.2 vs. 34.2%; p=0.017). In 27
patients, NBS was diagnosed following the onset of malignancies (mean age: 8 years).
Malignancies were mostly of lymphoid origin and predominantly non-Hodgkin lymphoma
(NHL) (n=42, 68%); 38% of patients had diffuse large B-cell lymphoma. The 20-year overall
survival rate of patients with malignancy was 24%. However, females with cancer experienced
poorer event-free survival rates than males (16.6% vs. 46.8%, p=0.036). Of 136 NBS patients,
13 underwent hematopoietic stem cell transplantation (HSCT) with an overall survival of 3.5
years following treatment (range: 1 to 14 years). Indications for HSCT included malignancy
(n=7) and immunodeficiency (n=6). Overall, 9% of patients in this cohort reached adulthood.
Adult survivors reported diminished quality of life with significant physical and cognitive
impairments. Our study highlights the need to improve timely diagnosis and clinical
management of NBS among Eastern Slavs. Genetic counseling and screening should be
offered to individuals with a family history of NBS, especially in hot spot regions.Keywords: Nijmegen breakage syndrome (NBS), founder variants, incidence in East Slavs, lymphomas, risk of
malignancies, geographical location, social adaptation, quality of lifeINTRODUCTION
Nijmegen breakage syndrome (NBS) is a syndromic combined
immunodeficiency with an autosomal-recessive inheritance. It is a
chromosome instability disorder with hypersensitivity to ionizing
radiation and aberrant cell-cycle checkpoint control and, therefore,
high susceptibility to lymphoid malignancies. Patients experience
growth delay and developmental defects with visible stigmata of
severe and progressive microcephaly, a distinct facial appearance
and lack of secondary sex characteristics in females. The disease is
caused by pathogenic variants in the NBN gene, which encodes
nibrin, a component of the complex involved in the cellular
response to DNA double-strand breaks (1–3).
Most patients with NBS originate from Central and Eastern
Europe with a Slavic background, and there is an accumulation of
patients in Poland, Southeast Germany, Czech Republic, Ukraine,
and Russia (3–5). Sporadic cases have been published in patients of
Middle Eastern origin (6, 7). The majority of NBS patients are
identified with a homozygous five base-pair deletion in the NBN
gene (c.657_661del5, p.K219fsX19) with a founder effect observed
in Caucasian European populations, especially of Slavic origin (8).
Increased morbidity and mortality in this cohort are related to
severe infections (in more than half of patients), autoimmune
complications (in up to 1/3 of patients), and malignancies (in
about half of patients) under the age of 20 years (9, 10).
Despite recent publications on the clinical manifestations,
immune abnormalities, and malignancies in patients with NBS, a
number of unresolved questions remain (8–10). The indication
for hematopoietic stem cell transplantation (HSCT) for primaryiersin.org 2immunodeficiency with or without malignancy is not well
defined in NBS. Mental health and psychosocial challenges
may also contribute to poor quality of life; however, there
remains a paucity of published data addressing these concerns.
Furthermore, family planning to prevent the birth of children
with NBS in geographic locations with the founder variant has
not been widely implemented.
In this report, we present data on a large NBS cohort of
genetically confirmed East Slavic patients with a specific focus on
geographic case distribution, incidence, oncological complications,
and outcome of treatment, including HSCT. In addition, we
investigate the quality of life and social adaptation of adult
survivors. The overall goal of our paper is to raise awareness of
additional NBS “hot spots” in Eastern Europe, beyond the Polish
region, and shed light on current medical and social challenges in
this vulnerable and still underserved population.MATERIAL AND METHODS
Patients
We conducted a multicenter retrospective study enrolling 136
NBS patients of Eastern Slavic origin from Belarus, Ukraine,
Russia, and Latvia (Russian origin of patients).
Ethics Statement
Informed consent forms were signed by the parents as requested
and approved by the institutional review boards of local
institutions involved. The protocol of study was approved byJanuary 2021 | Volume 11 | Article 602482
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for Pediatric Oncology, Hematology, and Immunology (IRB
protocol #0011715). Written informed consent for publishing
images of patients was obtained from each patient’s parents.
Study Design
A detailed questionnaire was administered to the treating
physicians to collect the following patient information:
demographics (gender, country, place and year of birth), history
ofmalignancy (primary and secondary cancer incidence, treatment,
transplantation), and overall survival (OS). We estimated the
prevalence of NBS in each country under study using data from
our study as well as published data, whereby the numerator was the
number of cases detected and the denominator was the number of
live births during the reported study period. The number of live
births inUkraine andBelaruswere calculatedbasedon reports from
Ukrainian and Belarusian State Statistics Services, respectively
(http://database.ukrcensus.gov.ua and https://www.belstat.gov.
by). We further divided each country into Western and Eastern
regions and compared the prevalence of NBS in these regions.
Additionally, we estimated the prevalence of NBS in theWest Slavs
(Poland, Czech Republic, Slovakia) using published data and
compared the prevalence of NBS in the East and West Slavs.
To examine the impact of the disease on patients’ quality of
life (QoL), we conducted a telephone survey with adult survivors
(n=11). Long-term social adaptation, an aspect of QoL, was
evaluated in terms of the attainment of adult life goals relating
to education, employment, and relationships (11). In addition,
we assessed patients’ self-reported QoL using the Medical
Outcomes Short Form-36 (SF-36) health survey (12). The
survey tool comprises 36 questions and yields an 8-scale profile
of scores as well as summary measures of physical and mental
health, known as the physical (PCS) and mental component
summary (MCS) measures. These eight domains can be
categorized into higher order clusters of physical health
(physical function, role–physical, bodily pain, general health)
and mental health (vitality, social function, role–emotional, and
mental health). Lower PCS and MCS scores reflect lower QoL
relating to physical and mental health status, respectively. These
measures have been used widely in health surveys (12). For each
patient surveyed, we quantified the whole score for both the PCS
and MCS and categorized clusters.
Mapping of Variants
Mapping was performed by the ArcGIS 10.5 program on the map
of Eastern Europe and Russia. The birthplace of patients is
indicated by the location of the blue circles.
Statistical Analysis
Descriptive statistical analyses were carried out for all scores of the
SF-36QoL.We quantified theOS of our cohort, defined as the time
from diagnosis to death from any cause based on data obtained on
the date of last follow-up. We further estimated event-free survival
(EFS) rates, defined as the time fromdiagnosis ofmalignancy to the
first adverse event (death, secondmalignancy) ordate of last follow-
up; patients transplanted in the first remission were excluded fromFrontiers in Immunology | www.frontiersin.org 3analysis of EFS (n=7). Cumulative incidence of malignancy (CIM)
was determined as the proportion of patients who developed the
first episode of cancer at a certain age.Analyses ofOS, EFS, andCIM
rates were performed using the Kaplan–Meier method and were
compared using a log-rank (Mantel–Cox) test. The Fisher exact test
was used to compare the incidence of malignancy in males and
females. All statistics were calculated with GraphPad Prism 6




Our study cohort comprised 136 patients with NBS. Of these, 76
cases have not been previously published, and 60 are previously
published but newly annotated cases (2, 13–17). One hundred
thirty-six patients (63 males, 73 females) from 127 families were
assessed, including 9 pairs of siblings and one family having two
half-siblings (16). The majority of our cohort is unrelated
individuals (n=109, 80%). As of February 1, 2019, 57 patients
were deceased and 79 (59%) were alive. The age of the patients
who were still alive ranged from 0.5 to 32 years (median age 11
years). Among all NBS patients, only 12 patients (8.9%) survived
beyond 18 years of age.
The clinical diagnosis of NBS was confirmed by the
identification of the pathogenic homozygous c.657_661del5
founder variant in the NBN gene in all subjects except one female
patient from Russia who had a compound heterozygous with the
combinationoffoundervariants, c.657_661del5andc.681delT (15).
A clinical description of our East Slavic NBS cohort is
summarized in Table 1.
The median age at diagnosis did not differ by countries
(Ukraine: median 4 years [range 0.1–16], Russia: 5 years [range
0.2–14], Belarus: 3.55 years [range 0.3–21]) (Figure S1A, in this
article’s Online Repository). Patients born in the capital or major
cities in each Eastern Slavic country were diagnosed at an earlier
age compared with those born in smaller cities or rural regions.
Median age of diagnosis was lower in Minsk and the Minsk
region (Belarus, Figure S1C) and in Moscow and the Moscow
region (Russia, Figure S1D). In Ukraine, patients residing in the
western part of the country, including Lviv and the Lviv region,
were diagnosed at an earlier age (Figure S1B).
We illustrate the geographic distribution of NBS patients
among Eastern Slavs on the map of Eastern Europe and the
Russian Federation (one patient from each family) (Figure 1).
The highest concentration of NBS patients was observed in
the western part of Belarus (Brest region) and Ukraine (Lviv
region and Ternopil), Latvia (Riga), and Russia (Moscow and
nearby regions) (Figures 1 and 2).
The western parts of Belarus and Ukraine share their border
with Poland, the country with the highest number of NBS
patients diagnosed in the world (10). Identification of patients
with NBS in Russia corresponds to resettlement of Russians in
the Russian Federation (Figures 1 and 2).January 2021 | Volume 11 | Article 602482
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Among Slavs
We estimate the prevalence of patients with NBS among Eastern
and Western Slavs using data from our cohort as well as
previously published reports (Table 2). Overall, our analysis
shows a greater prevalence of NBS in Western Slavs. Specifically,
Czech Republic (3.1 per 1,000,000, year 2016) (4) and Poland
(3.1 per 1,000,000, year 2015) (10) had the highest prevalence of
NBS patients, followed by Slovakia (2.6 per 1,000,000, year 2004).
In the Eastern Slavs, Belarus had the highest prevalence of NBS
(2.3 per 1,000,000, year 2018) (Table 2). The lower prevalence of
NBS in Ukraine (1.3 per 1,000,000, year 2018) and Russia (0.7
per 1,000,000, year 2018) may reflect that the settlement of this
area is not homogenous (Figure 1) although it should be noted
that Slavic people are the biggest population in Russia (Table 2).
We estimated the period prevalence of NBS over a 20-year
period, comparing the western and eastern regions of the countries
under study (Table S1). Our analysis shows that the western part of
Belarus and Ukraine represent the geographical center of NBSFrontiers in Immunology | www.frontiersin.org 4patients among Eastern Slavs (Figure 2). The period prevalence of
NBS patients ranged from 6.4 per 1,000,000 (Ivano-Frankovsk) to
24 per 1,000,000 (Lviv) inWest Ukraine—a territory that covers an
area of 131,256 km2 (8 regions, Table S1) with a population of
9,765,000 (year 2019) and 35 patients. The prevalence in West
Ukraine was estimated to be 3.6 per 1,000,000. Similarly, in the
western region of Belarus, where the highest prevalence was
estimated to be 21 per 1,000,000 (Brest) (Table S1), the
prevalence of NBS is higher than that in Poland and Czech
Republic (Table 2). Collectively, these data indicate that the
western parts of Ukraine and Belarus could be established as an
“East Slavic NBS hot spot and geographical center.”Demographic and Treatment
Characteristics of Patients With
Malignancy
Malignancy occurred in 62 (45.6%) patients with NBS. The CIM
by the age of 10 years amounted to 41.6% (n=44/105) andFIGURE 1 | The geographic distribution of NBS patients among East Slavs. Light gray zone on the map of Russia is the territory of predominant Russian settlement
(18). The size of the full circle correlates to the number of patients diagnosed from one location (or region) (range 1 to 9). In blue is the NBN founder variant
c.657_661del5, p.K219fsX19; in red: NBN c.657_661del5/c.681delT.TABLE 1 | Clinical description of Eastern Slavic cohort of NBS patients (n=136).
Country Number of patients,
gender




Death due to malignancy
(n, %)




1996-2017 23 (41%) 22 (39%) 15 (68%) 2/2
Russia n=53
17M, 36F





1993-2012 2 (40%) 4 (80%) 2 (50%) 0
Belarus n=22,
11M, 11F
1983-2017 7* (32%) 9 (41%) 6 (67%) 6/0January 2021 | VoluM, male, F, female, n, number.
*3 of 7 deceased patients were diagnosed postmortem.me 11 | Article 602482
Sharapova et al. Geographical Distribution, Incidence, Malignancies in NBSdramatically increased further to 71.6% (n=18/25) by the age of
20 years (Figure 3A). The male/female (M:F) ratio in patients
with cancer was approximately 1.5:1 (37 M and 25 F) although
the entire NBS cohort had a slight female predominance (1:1.2).
Malignancy developed significantly more often in males
(55.2%) than in females with NBS (34.2%) (p=0.017; Figure
3B) with a 26% increase in CIM for males by the age of 20 years
compared to females (79.2% vs. 52.9%, p=0.047) (Figure 3C).
However, those females with cancer had worse EFS rates than
males (long-term EFS 16.6% vs. 46.8%, p=0.036; Figure 3E). The
difference was most prominent after puberty (>14 years old).
Currently, 21 patients are alive (33.9%, 3 of 21 after HSCT), andFrontiers in Immunology | www.frontiersin.org 5the median follow-up is 17 months (range 0–248 months) for the
whole group of 62 NBS patients with malignancy.
Lymphoid neoplasms (91.9%) represent the vast majority of
malignancies with a slight predominance of T-lineage
malignancies (54.9%). Non-Hodgkin lymphomas (NHL) were
the most frequent disease and comprised about 2/3 (42 out of 62)
of all cases. The most common NHL subtypes were diffuse large
B-cell lymphoma (DLBCL) (n=16, 38.1%) and T-lymphoblastic
lymphoma (T-LBL) (n=13, 31.0%), followed by peripheral T-cell
lymphoma (PTCL) (n=5, 11.9%), Burkitt lymphoma (n=2, 4.8%),
B-cell NHL unspecified (n=2, 4.8%), and systemic ALK-positive
anaplastic large cell lymphoma in 1 case (2.4%). No data on NHLTABLE 2 | Prevalence of NBS patients among Eastern and Western Slavs.
Country Population (as of year studied) Number of patients Prevalence (per 1,000,000) Reference
East Slavs
Belarus 9,500,882 (2018) 22 2.3 Current study
Russia 118,764,737* (2018) 81 0.7 Current study and (9)
Ukraine 42,216,766 (2018) 56 1.3 Current study
West Slavs
Poland 38,437,239 (2015) 118 3.1 (10)
Czech Republic 10,597,473 (2016) 33 3.1 (4)
Slovakia 5,372,343 (2004) 14 2.6 (4)January 2021 | Volum*80.9% are Russians among 146,804,372 population of the Russian Federation.FIGURE 2 | Number of patients with NBS in geographical hot spot region. In blue is the NBN founder variant c.657_661del5, p.K219fsX19. The size of the full circle
correlates to the number of patients diagnosed from one location (or region). Blue circles represent number of cases (1 to >9).e 11 | Article 602482
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cases except one, the patients had an advanced stage of the disease
(Murphy stage III: 25, IV: 13). Remarkably, 75% of patients with
DLBCL showed lung involvement. Nine out of 13 with T-LBL had
generalized stage IV disease with bone marrow involvement.
Hodgkin lymphoma (HL) appeared to be a rare malignancy in
NBS patients with only 2 (3.3%). Both of them were diagnosed at a
relatively early age (5.7 and 6.6 years, respectively) in an advanced
stage (Ann-Arbor stage IV) and showed quite aggressive histology
(mixed cellularity and lymphocyte depleted subtype, respectively).
A total of 12 cases of acute lymphoblastic leukemia (ALL) were
diagnosed in our cohort with only one of B-lineage differentiation
(common-B immunophenotype).NineALLcaseswereofT-lineage
origin with the following immunophenotypes: ETP-ALL in 1 case,
cortical in3,pre-Tin3,andT-mature(CD8+)in2. Immunophenotyping
data were not provided in 2 ALL cases. Two other patients with
acute leukemia were diagnosed: one with acute biphenotypic (early
T/early myelo) and one with acute myeloid leukemia.
Solid tumors appeared to consist of a significant minority in
the cancer spectrum in the NBS cohort with only 4 (6.5%)
revealed cases (Table S2).
Given the retrospective and multi-institutional nature of the
study, detailed information regarding treatment was scarce. Five
patients did not receive special treatment (2 refused and 3 died
before therapy). Data about the treatment of 8 other patients were
notprovided. Forty-ninepatientswere treatedaccording toongoing
protocols (n=44) or individualized (n=5) and analyzed for
treatment results. Complete remission (CR) was achieved in 35
(71.4%) treated patients. Results varied depending onhistology andFrontiers in Immunology | www.frontiersin.org 6were studied in 12 out of 13 patients with T-LBL, 10 out of 12 cases
with ALL, 10 out of 15 cases with DLBCL, and 0 of 4 patients with
PTCL. It shouldbenoted that all 3 patientswithT-matureALL/LBL
responded poorly on induction chemotherapy but managed to
achieve CR after 1–3 high-risk courses of treatment. All 4 patients
with PTCL showed disease progression at different stages of
treatment. Nine (18.4%) deaths occurred before CR or before
recurrence occurred (7 during induction therapy and 2 later), and
5 deaths occurred during remission because of infections, bleeding,
or multiple organ dysfunction.
Disease recurrence occurred in 12 (24.5%) patients, including
progression in 7 and relapse in 5 cases. Median time to disease
recurrence was 8 months (range 1–67 months). No one achieved
second remission or survived.
A second malignancy occurred in 4 out of 21 (19.0%)
nontransplanted patients, who had a follow-up more than 3 years
after the first cancer diagnosis. The first tumor was NHL in all
cases (DLBCL in 3 and T-LBL in 1). We observed 1 case of
medulloblastoma and 3 cases of the second lymphoma,
diagnosed in 11.9, 4.4, 4.5, and 10.2 years, respectively after the
first malignancy. All 4 patients who developed the second
malignancy died due to various reasons.
Patients who developed cancer in our cohort had a lower 20-
year OS than those without malignancy (23.9% vs. 30.4%;
p=0.0078 Figure 4A).
Allogeneic HSCT
Among 136 NBS patients, HSCT was performed in 13 patients
(9.5%; 8 males and 5 females) (Table S3). The median age atA B
DC
FIGURE 3 | Malignancy data of the NBS East Slavic cohort. (A) Cumulative incidence of any malignancy (%) from birth in the whole NBS East Slavic cohort.
(B) Percentage of developed malignancy in boys and girls with NBS. (C) Cumulative incidence of any malignancy (%) among boys and girls in the NBS East Slavic
cohort. (D) EFS displayed as Kaplan–Meier survival curves in males and females after first malignant diagnosis. *p < 0.05.January 2021 | Volume 11 | Article 602482
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bone marrow (BM) in 10 patients. The donor was an unrelated
HLA match in 10 cases, and 3 cases were HLA-matched siblings.
Indication for HSCT was malignancy in 7 patients (in the first
CR in 4, in the second CR in 1, and after the second lymphoma in
2) and immunodeficiency in 6 cases (2 patients were transplanted
preemptively with mild signs of recurrent infections at the age of
1.9 and 2.2 years; 4 patients had chronic, severe infections of the
upper and lower respiratory tract, and 1 out of 4 additionally had
skin granuloma). Four patients with leukemia/lymphoma who
had undergone HSCT in the first CR are alive without evidence
of malignancy (follow-up period ranged from 11 months to 5.3
years). One patient with a relapse of ALL received myeloablative
conditioning and died soon after HSCT. All the others (91.7%)
received reduced-intensity conditioning (RIC) regimens (Table
S3). Three patients who were transplanted after the treatment
of relapsed ALL or second lymphoma, died of sepsis and
multiorgan failure before hematopoietic recovery or after relapse
of malignancy.
Of the 13 patients who underwent HSCT, acute graft-versus-host
disease (GVHD) was present in 5 (38.5%) patients and chronic
GVHD in 4 patients. Viremia caused by adenovirus, cytomegalovirus,
Epstein-Barr virus, BK virus or a combination was reported in 5
patients. None of the transplant patients fully rejected the graft.
HSCTafter theRIC regimenappeared tobe tolerable and effective
in NBS patients. Having 1 CR and a good performance status at the
time of HSCT are probably predictive of better outcomes.Frontiers in Immunology | www.frontiersin.org 7From the time of NBS diagnosis, the probability of 15-year OS
in patients who underwent HSCT was 61.5%. In contrast, patients
who did not undergo HSCT had a 15-year OS of 36.9% (Figure
4B). In total, 8 (61.5%) NBS patients are alive after HSCT without
de novo, recurrent, or second malignancies after a median length
of follow-up for 41 months (range 11–169 months). Among the 6
patients who underwent HSCT and did not have malignancy, 2
died of complications after HSCT (Table S3, Figure 4C).
Social Adaptation and QoL in Adult
NBS Patients
Of the 12 adult survivors in our cohort, 11 (6 males and 5
females) responded to our survey (2 male patients were
transplanted 14 and 5 years ago; their QoL scores were the
same as in patients who experienced malignancy many years
ago). The median age of these patients was 24.6 years (range 18–
32). Nine patients indicated some degree of independence (i.e.,
ability to take care of their routine needs). One female patient
had her own family, and all others lived with their parents. All
patients were able to attend school with their healthy peers and
completed their elementary school education. Two male patients
graduated from college but could not work in their profession.
One female patient graduated from a university and worked as a
psychologist with neurologically disabled and autistic children.
She was the only responder who enjoyed her job and had an
active hobby. This was also the only patient who reported strong
social support from her parents for education and socialization.BA
C
P1_male 1y P2_male 5y P3_male 22y
D
FIGURE 4 | Survival probabilities of 136 East Slavic NBS. (A) OS displayed as Kaplan–Meier survival curve of cancer (+) and no cancer NBS patient groups. (B) The
probability of the OS since NBS diagnosis in 13 patients who underwent HSCT and in 119 nontransplanted patients (expressed as a percentage, patients diagnosed
postmortem were excluded from analysis). (C) Survival probabilities of 13 NBS patients after HSCT. (D) NBS patients’ appearance at different ages.January 2021 | Volume 11 | Article 602482
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the 11 respondents confirmed socialization with peers.
We further evaluated patients’ QoL using the SF-36 Health
Survey. Our analysis shows that adult NBS patients had
substantially impaired QoL in both the physical and mental
domains (Figure S2). The subanalysis demonstrates remarkably
lower self-reported scores in physical functioning, role–physical,
bodily pain, and general health for most patients as well as in
vitality, social functioning, role–emotional, and mental health.
The overall role–physical (<25) and bodily pain and MCS (<23)
scores were remarkably lower (the healthy population has >83
scores as very good QoL [12]) (Figure S2) in patients who
experienced cancer in the last 1 to 2 years of life compared with
patients who experienced cancer in childhood.
Our study shows that adult NBS patients find substantially
impaired HRQoL in the physical and mental domains.
DISCUSSION
In our study,we present the largest East Slavic cohort of patientswith
NBSretrospectively collectedovera35-yearperiod (1983–2018).Our
analysisdemonstrates ahigherprevalenceofNBS in thewesternparts
ofUkraine andBelarus, particularly in regionsborderingPoland.The
presence of this East Slavic NBS geographical hot spot is consistent
with our previous study of RAG founder variants in Slavs, which
revealed the Vistula watershed as the geographic center of the
presumed origin of the p.K86fsTer33 RAG1 pathogenic variants
(19). Further studies are needed tounderstand the drivers behind this
trend and to address the needs of these patients.
A Slavic homozygous c.657_661del5 variant in the NBN gene
was found in all patients except one. A heterozygous compound
c.657_661del5/c.681delT was detected in a female patient from
Russia; the only reported case so far in the Slavic population (17).
AlthoughNBSpatients have characteristic features (Figure 4D),
immune and genetic evaluation was not initiated for all patients
early in life. Therefore, diagnosis of these children was delayed and
occurred in the context of malignancies. Consequently, other
preventive measures, such as intravenous immunoglobulin
replacement therapy, was delayed, which, in turn, increased
patients’ susceptibility to infections and contributed to challenges
in their management.
Consistent with previous studies, our study shows that 40% to
60% of NBS patients develop lymphoma or leukemia by the age
of 20 years (5, 9, 10). We observed 46% frequency of malignancy
in patients with NBS by the end of our follow-up period with
mostly lymphoid tumors (92%). However, in contrast with
published data (10), our cohort showed a slight predominance
of T-cell malignancies.
Survival rates of NBS patients with cancer were lower in
comparison with immunocompetent patients in all reports and
ranged from 18% to 40% (9, 10). Attention and awareness of
pediatricians may expedite immunological and molecular genetic
testing for children with suspected NBS and promote monitoring
for development of malignancy. According to our data, the risk of
tumor development in males with NBS is higher than in females
(65% and 35%, respectively, Figure 3B). However, the survival rateFrontiers in Immunology | www.frontiersin.org 8offemaleswith tumorswithoutHSCTis significantlyworse (17%vs.
47%, Figure 3D) andmay be partly due to the higher proportion of
prognostically unfavorable large cell lymphomas in females
compared with males. Larger studies are needed to determine the
predictive value of gender in NBS patients with malignancy.
Patients who developed cancer in our cohort had a lower 20-year
OS than those without malignancy (23.9% vs. 30.4%; p=0.0078;
Figure 4A). Our data are strikingly different from a previous Polish
study (10) that reported a 20-year OS of more than 80% in NBS
patients without cancer. Heterogeneity in patient characteristics
and treatments may have contributed to this inconsistency. Our
cohort comprised a higher number of younger patients.
Furthermore, poor medical treatment in adult patients with
severe complications caused by an underlying immunodeficiency
may have led to poorer survival outcome in our cohort.
Taking into account a progressive immunodeficiency with
deteriorating clinical state and extremely high risk of first and
subsequent lymphoid malignancies with uncertain curative
potential, allogeneic HSCT with RIC may be a rational
therapeutic option for NBS patients with severe defects of
immune function and for any NBS patients with lymphoid
malignancy in first remission (14). However, the biggest Russian
NBS study group reported that an RIC was a reason for a high level
of graft failure and mixed chimerism in NBS patients (20).
According to guidelines from the InbornErrorsWorkingParty of
theEuropeanBlood andMarrowTransplant Society, transplantation
is recommended for all NBS patients in first CR of lymphoma or
leukemia (21). In our study, a large fraction of the patients received
HSCT for indication of underlying immunodeficiency (6/13) and
67% (4/6) survived. This is a unique group and their cancer-free
survival outcomewill be followed in our future studies. Nevertheless,
there is still not enough data to recommend HSCT in all NBS even
with significant cellular immunodeficiency but without clinical
symptoms of immune deficiency (21).
QoL studies are scarce for patients with DNA repair defects
although the risk of malignancy and neurological sequelae are
very high in these groups. Current publications in patients with
ataxia telangiectasia focus on pulmonary and gastrointestinal
interventions and their effect on QoL (22, 23); however, social
and psychological assessment and HRQoL surveys are lacking in
the literature. This is of high importance as these assessments
could justify programs to advocate for children and their families
with NBS in hot spot regions.
Our very limited long-term study shows rare survival up to 30
years of age even without HSCT, and many of the patients had poor
social adaptation andQoLofdifferentdegrees. Patients’QoLstrongly
depended on family support as well on medical and social care.
Overall, our geographical studies show an East Slavic hot spot
region with a high prevalence of patients with NBS founder
mutation. Malignancies of lymphoid origin were frequent, and
HSCT was attempted to improve their outcome. In addition to
the high risk of malignancy, patients with NBS experience
psychosocial challenges, and interventions are needed to
promote their QoL. Genetic counseling and screening before
family planning should be considered for those with family
history of this disease, especially in the hot spot region.January 2021 | Volume 11 | Article 602482
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